New breakthrough in advanced HCC
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in…
Global survey reveals heavy toll of COVID-19 first wave on liver cancer care
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark…
On World Cancer Day, EASL warmly welcomes Europe’s Beating Cancer Plan
4 February 2021 The month of February brings together several key actions to tackle cancer globally, and EASL is focussing particularly on the global threat of liver cancer. EASL draws on all…
Liver community fights liver cancer with a robust action plan
Digital Liver Cancer Summit 2021: As the latest data suggests, liver cancer is now the third-most deadly cancer in the world, claiming nearly 1 million lives in 2020, the liver community takes…
A tribute to two driving forces in hepatology: Profs Gerok and Groszmann
In memoriam: Prof. Wolfgang Gerok (1926–2021) and Prof. Roberto Groszmann (1939–2021) 20 January 2021 EASL is greatly saddened to hear of the passing earlier this week of two giants of hepatology, Prof.…
Significant improvements in mechanistic biomarkers of how Dialive™ improves organ function
About EASL and the ALIVER Consortium The ALIVER Consortium of 11 institutions from seven European countries developed an innovative liver dialysis machine called Dialive™. This device helps the liver to regenerate naturally…
Looking towards bright horizons for 2021
This year has been unlike any other. COVID-19 brought unimaginable challenges to the medical community, placing you at the forefront of the pandemic. The year 2020 posed unique questions to those of…